Nov 7, 2022

Featuring an interview with Dr Rebecca Heist, including the following topics:

• Mechanism of action and toxicity of amivantamab in patients with MET-driven non-small cell lung cancer (NSCLC) (0:00)
• Potential role of MET inhibitors as pantumor treatment for MET-altered cancer (2:27)
• Selection and sequencing of targeted therapy for patients with MET-altered NSCLC (5:24)
• Managing MET-altered NSCLC in patients with brain metastases (7:55)
• Immune checkpoint inhibitors and MET-targeted therapy for patients with NSCLC and MET alterations (9:27)
• Case: A woman in her mid 60s with no smoking history and newly diagnosed NSCLC with a MET exon 14 skipping mutation (14:55)
• Case: A woman in her mid 70s with MET-amplified relapsed NSCLC with an EGFR L858R mutation  (24:02)
• Novel agents and strategies for the management of MET-altered NSCLC (32:00)

CME information and select publications